Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of 50561 tablets in mild to moderate Alzheimer's disease
CTR20230154Phase 2Completed
- Sponsor
- Beijing Zhuokai Biotechnology
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JK 50561 in Alzheimer's disease (AD), sponsored by Beijing Zhuokai Biotechnology. Started Apr 2023; status: completed.
02
Drugs
JK 50561
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20230154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230154.